Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Life Medical Sciences' Repel

This article was originally published in The Gray Sheet

Executive Summary

Pivotal trial in the U.S. employing the bioresorbable copolymer gel for prevention or reduction of adhesions following gynecological surgery will include 140 patients at roughly 14 sites and is slated to begin in the third quarter. Edison, New Jersey-based LMS announced investigational device exemption clearance April 30. Pilot study data show the product to be twice as effective in reducing adhesion formation compared to the control of standard surgical treatment; the device was particularly effective in treating adhesion formation on the posterior surface of the uterus ("The Gray Sheet" Dec. 22, In Brief). LMS is conducting a pilot study for Repel-CV for prevention of adhesions following cardiovascular surgery ("The Gray Sheet" March 30, p. 24) and has completed preclinical studies on Resolve, a bioresorbable viscous solution for reducing post-operative adhesions in gynecological and general abdominal surgeries. Preclinical studies are ongoing for Relieve gel for orthopedic use

You may also be interested in...

Dissecting The Impact: Chi-Med Details Coronavirus Experience

CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical. 

GNC In Rough Seas From COVID-19 Pandemic; Vitamin Shoppe Safe In Port Under New Owner

GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.

QUOTED. 7 April 2020. Surendar Magar.

California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts